Suchergebnisse - "Cortes, Javier"

PubPharm (69)

1

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Gebhart, G. | Keyaerts, M. | Guiot, T. | +23

2

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain) : a randomised, open-label, phase 2 trial

enthalten in: Lancet (London, England) | 2024

von Pérez-García, J. | Cortés, J. | Ruiz-Borrego, M. | +27

3

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

enthalten in: International journal of molecular sciences | 2024

von Franco-Mateos, E. | Souza-Egipsy, V. | García-Estévez, L. | +11

4

Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy : A systematic review and meta-analysis

enthalten in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2023

von Salvestrini, V. | Kim, K. | Caini, S. | +19

5

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain

enthalten in: International journal of molecular sciences | 2023

von Cruz, V. | Souza-Egipsy, V. | Gion, M. | +4

6

Systemic treatment for brain metastasis in HER2- positive advanced breast cancer : what have we learned so far?

enthalten in: Oncotarget | 2023

von Batista, M. | Perez-Gracia, J. | Eiriz, I. | +4

7

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Squifflet, P. | Saad, E. | Loibl, S. | +27

ErratumIn: J Clin Oncol. 2023 Dec 19;:JCO2302620. - PMID 38113406

8

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von van Mackelenbergh, M. | Loibl, S. | Untch, M. | +27

9

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer : Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA network open | 2023

von Pivot, X. | Cortés, J. | Lüftner, D. | +17

CommentIn: JAMA Netw Open. 2023 Apr 3;6(4):e235776. - PMID 37022693

10

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer : A Correlative Analysis of the CALGB 40601 and PAMELA Trials

enthalten in: JAMA oncology | 2023

von Fernandez-Martinez, A. | Pascual, T. | Singh, B. | +16

1
2
3
4
5
6
7
Nächster »
[7]